Abstract |
Brefeldin A (BFA), a well-known natural Arf-GEFs inhibitor, is effective against hepatocellular carcinoma (HCC), while the poor solubility, serious toxicity, and short half-life limit its potential. Herein, distinct corresponding prodrugs of BFA, including esters 1-15, carbonates 16-24 and 30-32, and carbamates 25-29, were synthesized and evaluated. CHNQD-01255 (16) with improved aqueous solubility (15-20 mg/mL) demonstrated favorable pharmacokinetic profiles. It behaved as expected by undergoing rapid conversion to BFA in vivo, and achieved sufficient high plasma exposure, prolonged half-life, as well as the improved bioavailability of BFA (F = 18.96%). Meanwhile, CHNQD-01255 significantly suppressed tumor growth (TGI = 61.0%) at a dose of 45 mg/kg (p.o.) in the xenograft model. Notably, the improved safety profile of CHNQD-01255 (MTD > 750 mg/kg, p.o.) was confirmed to be superior to that of BFA (MTD < 506 mg/kg). Overall, CHNQD-01255 may serve as a safe and effective new anti-HCC prodrug.
|
Authors | Yao-Yao Jiang, Yang Gao, Jian-Yu Liu, Ying Xu, Mei-Yan Wei, Chang-Yun Wang, Yu-Cheng Gu, Chang-Lun Shao |
Journal | Journal of medicinal chemistry
(J Med Chem)
Vol. 65
Issue 18
Pg. 11970-11984
(09 22 2022)
ISSN: 1520-4804 [Electronic] United States |
PMID | 36089748
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Carbamates
- Prodrugs
- Brefeldin A
|
Topics |
- Animals
- Brefeldin A
(pharmacology)
- Carbamates
- Carcinoma
- Cell Line
- Cell Proliferation
(drug effects)
- Humans
- Mice
- Prodrugs
(chemical synthesis, pharmacokinetics, pharmacology, therapeutic use)
|